• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    AstraZeneca Pharma India Ltd.
    06 Sep 2025
    8996.00
    -1.15%
    AstraZeneca to invest 176 cr to expand GITC in Chennai
    Business Line
    The new investment, third in the past two years in India, will expand the GITC to strengthen its position as a leader in healthcare innovation both globally and in the country
    Copy LinkShare onShare on Share on Share on
    AstraZeneca Pharma India Ltd. is trading above all available SMAs
    Ashok Leyland to invest 7,500 cr in TN, AstraZeneca to expand GITC
    Business Standard | 06 Sep 2025
    logo
    Sun Pharmaceutical Industries Ltd.
    05 Sep 2025
    US FDA Classification
    1593.40
    0.11%
    Pharma market grows 8.7% in August; cardiac and anti-diabetic segments lead
    Business Standard
    The Indian Pharma Market grew 8.7% in August 2025, with the cardiac, anti-diabetic, and anti-neoplastic segments driving growth. Sun Pharma maintained its leadership position
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 1351 to 1326 in Jun 2025 qtr
    logo
    Cipla Ltd.
    05 Sep 2025
    1563.80
    0.79%
    Cipla launches Huena, India's first non-antibiotic drug to fight UTI
    Business Standard
    Drug firm Cipla on Friday said it has introduced a non-antibiotic treatment for patients suffering from recurrent urinary tract infections. The company has launched Methenamine Hippurate under the brand name HUENA. This marks a significant step forward for the company in its fight against anti-microbial resistance as it becomes the first to introduce such treatment in India, the Mumbai-based drugmaker said in a statement. Urinary tract infections (UTIs) are the second most common reason for antibiotic use in India, with infection cases doubling over the last 30 years. Women are more susceptible to UTIs, which account for 15 per cent of overall antibiotic prescriptions. Methenamine Hippurate offers an effective, non-antibiotic alternative for preventing UTIs by targeting bacteria in the bladder and urinary tract. Studies show it is as effective as long-term, low-dose antibiotic therapy for UTI prevention, with lower costs and no risk of antibiotic resistance. "We believe this...
    Copy LinkShare onShare on Share on Share on
    Deven Choksey released a Hold report for Cipla Ltd. with a price target of 1570.0 on 08 Sep, 2025.
    logo
    Torrent Pharmaceuticals Ltd.
    04 Sep 2025
    3591.70
    -1.42%
    Torrent Pharma Announces Open Offer To Acquire Rs 6,843-Crore Stake In JB Chemicals
    Torrent Pharma Announces Open Offer To Acquire Rs 6,843-Crore Stake In JB Chemicals
    NDTV Profit
    Once the deal is finalised, Torrent Pharmaceuticals will become India's second most valued pharma company.
    Copy LinkShare onShare on Share on Share on
    Torrent Pharmaceutic.. has an average target of 3746.00 from 5 brokers.
    logo
    Sequent Scientific Ltd.
    04 Sep 2025
    183.17
    -2.36%
    Sequent and Viyash Life merger plan gets shareholder approval
    Sequent and Viyash Life merger plan gets shareholder approval
    Economic Times
    The proposed merger of Sequent Scientific and Viyash Life Sciences, backed by Carlyle, has received overwhelming shareholder support. This 8,000-crore merger aims to create a global entity, combining Sequent's animal health focus with Viyash's human health expertise. Hari Babu Bodepudi, the proposed group CEO, highlights opportunities in animal health generics and leveraging synergies between the companies' manufacturing capabilities.
    Copy LinkShare onShare on Share on Share on
    Sequent Scientific Ltd. is trading above all available SMAs
    logo
    Pfizer Ltd.
    03 Sep 2025
    5140.50
    -0.24%
    Pfizer Defends Covid Shot, Says Trump Deserves Nobel Prize
    Pfizer Defends Covid Shot, Says Trump Deserves Nobel Prize
    NDTV Profit
    Vaccines have become a political flashpoint in recent years, with pundits questioning widely accepted evidence about their safety and efficacy.
    Copy LinkShare onShare on Share on Share on
    Pfizer Ltd. is trading above its 200 day SMA of 4899.2
    logo
    Lupin Ltd.
    03 Sep 2025
    US FDA Observation
    1979.70
    1.14%
    Lupin Gets USFDA Nod For Generic Risperidone Extended-Release Injectable Suspension
    Lupin Gets USFDA Nod For Generic Risperidone Extended-Release Injectable Suspension
    NDTV Profit
    The medicine had estimated annual sales of $190 million in the US, Lupin said, citing IQVIA moving annual toal July 2025 data.
    Copy LinkShare onShare on Share on Share on
    Lupin Ltd. has an average target of 2326.00 from 8 brokers.
    Lupin gets USFDA nod for generic risperidone extended-release injectable suspension
    Business Line | 03 Sep 2025 1 more
    Lupin share price rises 3% as USFDA okays schizophrenia drug; details
    Business Standard | 03 Sep 2025
    logo
    Caplin Point Laboratories Ltd.
    03 Sep 2025
    Dividend
    2219.70
    0.72%
    Caplin Point's unit gets USFDA nod for generic milrinone lactate injection
    Business Standard
    Pharma firm Caplin Point Laboratories Ltd on Wednesday said its arm Caplin Steriles Ltd has received final approval from the US health regulator for its generic milrinone lactate in 5 per cent dextrose injection indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. The approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) milrinone lactate in 5 per cent Dextrose Injection of strengths 20 mg/100 mL and 40 mg/200 mL in single-dose infusion bags, Caplin Point Laboratories said in a regulatory filing. The approved injection is a generic therapeutic equivalent version of the reference listed drug PRIMACOR in dextrose 5 per cent, by Sanofi Aventis US LLC, it added. Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure, the company said. Citing IQVIA (IMS Health) data, the company said milrinone lactate in 5 per cent...
    Copy LinkShare onShare on Share on Share on
    Caplin Point Laboratories Ltd. is trading above all available SMAs
    logo
    Anlon Healthcare Ltd.
    03 Sep 2025
    10-year high
    106.64
    4.99%
    Anlon Healthcare makes flat D-street debut, lists at 92 on NSE SME
    Business Standard
    Post-listing, the Anlon Healthcare stock was trading at 91.5, up 0.55 per cent from the listing price on the BSE
    Copy LinkShare onShare on Share on Share on
    Anlon Healthcare Ltd. has gained 17.19% in the last 1 Week
    logo
    AstraZeneca Pharma India Ltd.
    02 Sep 2025
    8996.00
    -1.15%
    AstraZeneca surrenders its manufacturing licence in India
    Business Line
    The company is looking at importing its products from the 20-odd facilities it has across the world as part of a global review, said a source
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 164 to 181 in Jun 2025 qtr.
    more
    loading
    Logo Trendlyne

    Stay ahead of the market

    Company

    PrivacyDisclaimerTerms of Use Contact Us

    Resources

    Blog FAQsStock Market Widgets

    Copyright © 2025 Giskard Datatech Pvt Ltd